We analyze the latest studies carried out regarding post-vacial protection against coronavirus and the appearance of new medications.
Reduce treatment time without losing effectiveness
Following correctly the prescribed treatment is essential for its effectiveness.
We participated in the conversation Hepatitis C: Challenge for health, promoted by Fuinsa and Servimedia and that took place in the Press Association of Madrid.
TG4040 is a modified Ankara vaccine virus that expresses the hepatitis C virus NS3, NS4 and NS5B proteins (therapeutic vaccine). The Foundation participated in a phase II clinical trial in patients with chronic hepatitis C.
A new study by members of the Foundation for the Study of Viral Hepatitis on the presence of hidden hepatitis C in patients with chronic hepatitis B is published in the Journal of Medical Microbiology.
In January of this year two important studies of Hepatitis C treatment without interferon have been published. So Kowdley et al (NEJMed, 222-232) have used three inhibitory drugs from different areas of the C virus.
Currently there are antiviral treatments against chronic hepatitis C (pegylated interferon + ribavirin + inhibitors) with a favorable response in 75% of cases. However, these treatments can have important side effects and contraindications for its administration.